vs
Side-by-side financial comparison of ClearSign Technologies Corp (CLIR) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $3.7M, roughly 1.5× ClearSign Technologies Corp). ClearSign Technologies Corp runs the higher net margin — -8.5% vs -507.8%, a 499.3% gap on every dollar of revenue. On growth, ClearSign Technologies Corp posted the faster year-over-year revenue change (522.2% vs 171.3%). Over the past eight quarters, ClearSign Technologies Corp's revenue compounded faster (82.5% CAGR vs 26.8%).
ClearSign Technologies Corporation (ClearSign) is a United States-based company that develops emission-control technology.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
CLIR vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.7M | $5.5M |
| Net Profit | $-311.0K | $-27.9M |
| Gross Margin | 21.9% | — |
| Operating Margin | -22.5% | -516.0% |
| Net Margin | -8.5% | -507.8% |
| Revenue YoY | 522.2% | 171.3% |
| Net Profit YoY | 73.3% | -48.3% |
| EPS (diluted) | $-0.06 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.7M | $5.5M | ||
| Q3 25 | $1.0M | $0 | ||
| Q2 25 | $133.0K | $2.0M | ||
| Q1 25 | $401.0K | $2.3M | ||
| Q4 24 | $590.0K | $2.0M | ||
| Q3 24 | $1.9M | $1.8M | ||
| Q2 24 | $45.0K | $1.1M | ||
| Q1 24 | $1.1M | $3.4M |
| Q4 25 | $-311.0K | $-27.9M | ||
| Q3 25 | $-1.4M | $-32.7M | ||
| Q2 25 | $-1.7M | $-26.9M | ||
| Q1 25 | $-2.1M | $-21.5M | ||
| Q4 24 | $-1.2M | $-18.8M | ||
| Q3 24 | $-1.2M | $-25.5M | ||
| Q2 24 | $-1.9M | $-20.9M | ||
| Q1 24 | $-1.1M | $-24.1M |
| Q4 25 | 21.9% | — | ||
| Q3 25 | 35.8% | — | ||
| Q2 25 | 41.4% | — | ||
| Q1 25 | 48.9% | — | ||
| Q4 24 | 14.9% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 93.3% | — | ||
| Q1 24 | 39.7% | — |
| Q4 25 | -22.5% | -516.0% | ||
| Q3 25 | -170.1% | — | ||
| Q2 25 | -1382.0% | -1347.1% | ||
| Q1 25 | -562.8% | -930.5% | ||
| Q4 24 | -282.4% | -985.8% | ||
| Q3 24 | -77.1% | -1448.4% | ||
| Q2 24 | -4748.9% | -1915.4% | ||
| Q1 24 | -113.6% | -713.3% |
| Q4 25 | -8.5% | -507.8% | ||
| Q3 25 | -138.9% | — | ||
| Q2 25 | -1263.2% | -1353.6% | ||
| Q1 25 | -517.7% | -935.2% | ||
| Q4 24 | -197.3% | -929.0% | ||
| Q3 24 | -62.1% | -1427.5% | ||
| Q2 24 | -4160.0% | -1882.0% | ||
| Q1 24 | -100.5% | -705.4% |
| Q4 25 | $-0.06 | $-0.08 | ||
| Q3 25 | $-0.26 | $-0.09 | ||
| Q2 25 | $-0.30 | $-0.09 | ||
| Q1 25 | $-0.37 | $-0.08 | ||
| Q4 24 | $-0.18 | $-0.07 | ||
| Q3 24 | $-0.20 | $-0.10 | ||
| Q2 24 | $-0.40 | $-0.09 | ||
| Q1 24 | $-0.30 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.2M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.5M | $246.9M |
| Total Assets | $12.2M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $319.8M | ||
| Q3 25 | $10.5M | $297.3M | ||
| Q2 25 | $12.3M | $312.8M | ||
| Q1 25 | $12.9M | $116.6M | ||
| Q4 24 | $14.0M | $139.0M | ||
| Q3 24 | $14.5M | $157.7M | ||
| Q2 24 | $16.0M | $172.7M | ||
| Q1 24 | $4.6M | $124.0M |
| Q4 25 | $9.5M | $246.9M | ||
| Q3 25 | $9.1M | $219.0M | ||
| Q2 25 | $10.4M | $248.7M | ||
| Q1 25 | $12.0M | $55.1M | ||
| Q4 24 | $13.8M | $71.5M | ||
| Q3 24 | $14.8M | $88.8M | ||
| Q2 24 | $15.9M | $108.9M | ||
| Q1 24 | $4.5M | $53.8M |
| Q4 25 | $12.2M | $343.3M | ||
| Q3 25 | $12.7M | $316.6M | ||
| Q2 25 | $14.2M | $333.3M | ||
| Q1 25 | $14.5M | $138.4M | ||
| Q4 24 | $16.3M | $160.4M | ||
| Q3 24 | $17.1M | $180.2M | ||
| Q2 24 | $17.8M | $200.4M | ||
| Q1 24 | $6.6M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.3M | $-26.7M | ||
| Q3 25 | $-1.8M | $-24.2M | ||
| Q2 25 | $-511.0K | $-20.2M | ||
| Q1 25 | $-1.1M | $-22.0M | ||
| Q4 24 | $-415.0K | $-18.3M | ||
| Q3 24 | $-1.4M | $-21.6M | ||
| Q2 24 | $-1.5M | $-21.5M | ||
| Q1 24 | $-1.0M | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | $-1.1M | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -278.1% | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 0.0% | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
